XINT.ST
Price:
$0.254
Market Cap:
$178.65M
Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple neg...[Read more]
Industry
Biotechnology
IPO Date
2016-03-22
Stock Exchange
STO
Ticker
XINT.ST
According to Xintela AB (publ)’s latest financial reports and current stock price. The company's current PE Ratio is -3.63. This represents a change of -38.80% compared to the average of -5.93 of the last 4 quarters.
The mean historical PE Ratio of Xintela AB (publ) over the last ten years is -6.56. The current -3.63 PE Ratio has changed 5.43% with respect to the historical average. Over the past ten years (40 quarters), XINT.ST's PE Ratio was at its highest in in the June 2022 quarter at -0.51. The PE Ratio was at its lowest in in the September 2018 quarter at -21.65.
Average
-6.56
Median
-6.15
Minimum
-12.94
Maximum
-1.33
Discovering the peaks and valleys of Xintela AB (publ) PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 129.45%
Maximum Annual PE Ratio = -1.33
Minimum Annual Increase = -76.29%
Minimum Annual PE Ratio = -12.94
| Year | PE Ratio | Change |
|---|---|---|
| 2024 | -4.83 | 129.45% |
| 2023 | -2.10 | 58.40% |
| 2022 | -1.33 | -75.69% |
| 2021 | -5.46 | 1.17% |
| 2020 | -5.40 | -20.90% |
| 2019 | -6.83 | -47.23% |
| 2018 | -12.94 | 83.25% |
| 2017 | -7.06 | -21.88% |
| 2016 | -9.04 | -15.02% |
| 2015 | -10.63 | -76.29% |
The current PE Ratio of Xintela AB (publ) (XINT.ST) is less than than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-2.75
5-year avg
-3.82
10-year avg
-6.56
Xintela AB (publ)’s PE Ratio is greater than Elicera Therapeutics AB (publ) (-21.88), greater than Intervacc AB (publ) (-4.83), greater than Acarix AB (publ) (-6.73), greater than Ascelia Pharma AB (publ) (-3.94), less than Mendus AB (publ) (-2.43), less than Karolinska Development AB (publ) (-0.75), greater than Nanexa AB (publ) (-12.41), greater than Lipum AB (publ) (-4.04), greater than Bio-Works Technologies AB (publ) (-6.10), less than IRLAB Therapeutics AB (publ) (-1.79),
| Company | PE Ratio | Market cap |
|---|---|---|
| -21.88 | $285.39M | |
| -4.83 | $306.05M | |
| -6.73 | $348.35M | |
| -3.94 | $349.62M | |
| -2.43 | $249.20M | |
| -0.75 | $100.23M | |
| -12.41 | $484.76M | |
| -4.04 | $308.64M | |
| -6.10 | $178.63M | |
| -1.79 | $164.62M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Xintela AB (publ) using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Xintela AB (publ) or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Xintela AB (publ)'s PE Ratio?
How is the PE Ratio calculated for Xintela AB (publ) (XINT.ST)?
What is the highest PE Ratio for Xintela AB (publ) (XINT.ST)?
What is the 3-year average PE Ratio for Xintela AB (publ) (XINT.ST)?
What is the 5-year average PE Ratio for Xintela AB (publ) (XINT.ST)?
How does the current PE Ratio for Xintela AB (publ) (XINT.ST) compare to its historical average?